Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection-Reference-Cited by-同舟云学术

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection

Published:2023-01-24 Issue:1 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Burdette Dara¹,Hyrina Anastasia¹^ORCID,Song Zhijuan¹,Beran Rudolf K.¹,Cheung Tara¹,Gilmore Sarah¹,Kobayashi Tetsuya¹,Li Li¹^ORCID,Liu Yang¹^ORCID,Niedziela-Majka Anita¹,Medley Jonathan¹,Mehra Upasana¹,Morganelli Philip¹,Novikov Nikolai¹,Niu Congrong¹,Tam Danny¹,Tang Jennifer¹,Wang Jianhong¹,Yue Qin¹,Fletcher Simon P.¹,Holdorf Meghan M.¹,Delaney William E.¹,Feierbach Becket¹,Lazerwith Scott¹

Affiliation:

1. Gilead Sciences, Inc., Foster City, California, USA

Abstract

The standard of care for the treatment of chronic hepatitis B (CHB) is typically lifelong treatment with nucleos(t)ide analogs (NAs), which suppress viral replication and provide long-term clinical benefits. However, infectious virus can still be detected in patients who are virally suppressed on NA therapy, which may contribute to the failure of these agents to cure most CHB patients.

Funder

Gilead Sciences

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01348-22

Reference56 articles.

1. WHO. 2021. Global progress report on HIV, viral hepatitis and sexually transmitted infections. WHO, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240027077.

2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

3. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

4. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

5. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medicinal chemistry strategies in the discovery and optimization of HBV core protein allosteric modulators (2018–2022 update);Chinese Chemical Letters;2023-11

2. Structure-based Design of Novel Hepatitis B Virus Capsid Assembly Modulators;Bioorganic & Medicinal Chemistry Letters;2023-09

3. Current and novel modalities for management of chronic hepatitis B infection;World Journal of Hepatology;2023-05-27

4. Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival;Microbiology Research;2023-04-06

5. Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice;European Journal of Medicinal Chemistry;2023-03